Given different scientific and clinical meeting schedules, considering advances in genitourinary oncology in novel therapies ...

The “off-the-shelf” CAR T-cell therapy CTD402 will be evaluated in a phase 1b/2 trial for patients with T-cell acute ...

An expert discusses the safety findings from the PEACE-3 study, highlighting the adverse events associated with the ...

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer ...

Updated ASCO guidelines for pleural mesothelioma refine surgery use, recommend immunotherapy, genetic testing, and improve ...

A panelist discusses how treatment sequencing decisions in RCC span multiple lines of therapy, incorporating various options like tivozanib, lenvatinib-everolimus combinations, and belzutifan, with ...

A panelist discusses how second-line therapy selection in metastatic RCC requires careful consideration of multiple factors including prior treatment response, individual patient characteristics, ...

Nam Quoc Bui, MD, discusses survival, symptom control, and ovarian toxicity in the DeFi trial of nirogacestat in patients with desmoid tumors.

Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

A phase 1/2 trial is evaluating HLD-0915, a novel oral therapy, for metastatic castration-resistant prostate cancer in up to ...

The investigational immunotherapy bexmarilimab has been granted orphan drug designation from the FDA for patients with ...

Panelists discuss individualized treatment selection for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on targeted therapies and personalized approaches to improve patient ...